172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM)

• Andrew Weinberg,
• Ryan Montler,
• Colin Thalhofer,
• Tarsem Moudgil,
• Bernard Fox,
• Melissa Maxwell,
• Dingxue Yan,
• James Cardia,
• Simon Fricker,
• Jacob Moses,
• Nick Morris,
• B Bell

Affiliations

Andrew Weinberg

Aff1 Earle A Chiles Cancer Research Institute/Providence Cancer Center Portland OR USA

Ryan Montler

Aff1 Agonox, Inc Portland OR USA

Colin Thalhofer

Aff1 Agonox, Inc Portland OR USA

Tarsem Moudgil

Aff3 grid.415337.7Earle A. Chiles Research InstituteProvidence Cancer Center Portland USA

Bernard Fox

Aff3 grid.415337.7Earle A. Chiles Research InstituteProvidence Cancer Center Portland USA

Melissa Maxwell

2Phio Pharmaceuticals, Marlborough, MA, USA

Dingxue Yan

2Phio Pharmaceuticals, Marlborough, MA, USA

James Cardia

2Phio Pharmaceuticals, Marlborough, MA, USA

Simon Fricker

2Phio Pharmaceuticals, Marlborough, MA, USA

Jacob Moses

1Agonox Inc., Portland, OR, USA

Nick Morris

1Agonox Inc., Portland, OR, USA

B Bell

3EACRI, Providence Cancer Center, Portland, OR, USA